1	5 subject must discontinue use of steroid muscle relaxant anticonvulsant sodium channel blocker topical analgesic and needle-based therapy include trigger point injection and acupuncture at least 1 week prior to start study medication and agree to stay off such therapy throughout the study continuation|sodium channel blocker[73,95]|||||topical[96,103]||1 week[196,202]||C2936807|1002249|1002249|sodium channel blocker
1	5 subject must discontinue use of steroid muscle relaxant anticonvulsant sodium channel blocker topical analgesic and needle-based therapy include trigger point injection and acupuncture at least 1 week prior to start study medication and agree to stay off such therapy throughout the study continuation|anticonvulsant[58,72]||||||||||926|926|anticonvulsant
1	5 subject must discontinue use of steroid muscle relaxant anticonvulsant sodium channel blocker topical analgesic and needle-based therapy include trigger point injection and acupuncture at least 1 week prior to start study medication and agree to stay off such therapy throughout the study continuation|muscle relaxant[42,57]||||||||||1028434|1028434|muscle relaxant
1	5 subject must discontinue use of steroid muscle relaxant anticonvulsant sodium channel blocker topical analgesic and needle-based therapy include trigger point injection and acupuncture at least 1 week prior to start study medication and agree to stay off such therapy throughout the study continuation|steroid[34,41]||||||||||10072|10072|steroid
2	of nonsteroidal anti-inflammatory antidepressant and opiate be allow provide they have reach a stable dose prior to study entry and maintain a stable dose throughout the study|antidepressant[338,352]||||||||||927|927|antidepressant
2	of nonsteroidal anti-inflammatory antidepressant and opiate be allow provide they have reach a stable dose prior to study entry and maintain a stable dose throughout the study|opiate[357,363]||||||||||114189|114189|opiates
